ESR1 and neoplasm: For example, CAFs drive resistance to HER2-targeted therapies (24, 26, 27, 28), suppress apoptotic programs (24), promote chemoresistance (29), support tumor stem cells (30), and reduce effectiveness of ER-targeting therapies (24, 25, 31).